Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

BRAF and K-RAS Mutation in a Greek Papillary and Medullary Thyroid Carcinoma Cohort

NIKOLAOS GOUTAS, DIMITRIOS VLACHODIMITROPOULOS, MYRTO BOUKA, ANDREAS C. LAZARIS, GEORGE NASIOULAS and MARIA GAZOULI
Anticancer Research January 2008, 28 (1A) 305-308;
NIKOLAOS GOUTAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIMITRIOS VLACHODIMITROPOULOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MYRTO BOUKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREAS C. LAZARIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGE NASIOULAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA GAZOULI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mgazouli@med.uoa.gr
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The genes RAS and BRAF have been shown to be frequently mutated in human thyroid carcinomas. The aim of this study was to genotype a cohort of 55 sporadic papillary thyroid carcinomas (PTC) and 44 sporadic medullary thyroid carcinomas (MTC) for the K-RAS codon 12 and BRAF codon 600 mutations. Materials and Methods: K-RAS and BRAF mutations were characterized by an enhanced polymerase chain reaction followed by restriction fragment length polymorphism analysis (PCR-RFLP). Results: The K-RAS codon 12 mutation was found in 54.5% of the PTC and 40.9% of the MTC cases tested. The BRAF V600E mutation was detected in 27.3% of the PTC and 68.2% of the MTC samples. No significant association between K-RAS and BRAF mutations and clinicopathological parameters was found. Conclusion: These data indicate that K-RAS and BRAF mutations were a frequent genetic event in our samples of sporadic PTC and MTC.

  • BRAF
  • K-RAS
  • mutation
  • papillary
  • medullary
  • thyroid carcinoma
  • Received September 10, 2007.
  • Revision received November 16, 2007.
  • Accepted December 14, 2007.
  • Copyright© 2008 International Institute of Anticaner Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (1A)
Anticancer Research
Vol. 28, Issue 1A
January-February 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
BRAF and K-RAS Mutation in a Greek Papillary and Medullary Thyroid Carcinoma Cohort
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
12 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
BRAF and K-RAS Mutation in a Greek Papillary and Medullary Thyroid Carcinoma Cohort
NIKOLAOS GOUTAS, DIMITRIOS VLACHODIMITROPOULOS, MYRTO BOUKA, ANDREAS C. LAZARIS, GEORGE NASIOULAS, MARIA GAZOULI
Anticancer Research Jan 2008, 28 (1A) 305-308;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
BRAF and K-RAS Mutation in a Greek Papillary and Medullary Thyroid Carcinoma Cohort
NIKOLAOS GOUTAS, DIMITRIOS VLACHODIMITROPOULOS, MYRTO BOUKA, ANDREAS C. LAZARIS, GEORGE NASIOULAS, MARIA GAZOULI
Anticancer Research Jan 2008, 28 (1A) 305-308;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis
  • Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps
  • Putative BRAF activating fusion in a medullary thyroid cancer
  • RAS proto-oncogene in medullary thyroid carcinoma
  • Gene expression profile of human thyroid cancer in relation to its mutational status
  • Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
  • Targeting the RET Pathway in Thyroid Cancer
  • Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets
  • Google Scholar

More in this TOC Section

  • Tissue Prognostic Markers for Clear Cell Renal Cell Carcinoma Tumor-stroma Interaction: Impact on TNM Staging Parameters
  • CA9-Positive Keloid Fibroblasts: Modulator of Local Inflammation Induced by the Hypoxic and Glycolysis-enhanced Microenvironment
  • Predictive Factors for Multiple Metastases of Clear-cell Renal Cell Carcinoma
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire